60397-35-5Relevant academic research and scientific papers
Androstene-3,5-dienes as ER-β selective SERMs
Blizzard, Timothy A.,Gude, Candido,Morgan II, Jerry D.,Chan, Wanda,Birzin, Elizabeth T.,Mojena, Marina,Tudela, Consuelo,Chen, Fang,Knecht, Kristin,Su, Qin,Kraker, Bryan,Mosley, Ralph T.,Holmes, Mark A.,Rohrer, Susan P.,Hammond, Milton L.
, p. 6295 - 6298 (2008/09/17)
A series of androstene-3,5-diene derivatives were prepared. Despite lacking the C-3 hydroxyl previously believed necessary for ER activity, some of the analogs retained surprising affinity for ER-β. For example, diene 4 retained excellent selectivity and potency as an ER-β agonist and was more selective for ER-β over the androgen receptor (AR).
ESTROGEN RECEPTOR MODULATORS
-
Page/Page column 33, (2008/06/13)
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget’s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
